Global
Excipients for Drug Formulation
Kollicoat® MAE 100-55
A complete match – just better. Kollicoat® MAE 100-55 combines two things hard to bring together – it can directly exchange the comparable pH 5.5 enteric release coating polymer in your commercial formulations, and still bring significant handling improvement to your operators because it does not dust at all.
Kollicoat® MAE 100-55 is the latest addition to our comprehensive portfolio of functional excipients in our Instant & Modified Release Platform. It extends our offer of pH >5.5 enteric release products based on methacrylic acid-ethylacrylate copolymer, providing you even more flexibility.
Why choose Kollicoat® MAE 100-55
- Direct substitution in commercial enteric release formulations based on methacrylic acid-ethylacrylate copolymer with an opening pH > 5.5
- Easier handling due to dust-free material
- Compliant with respective monographs
No more dusting thanks to unique powder particle shape
The dry powder particles of Kollicoat® MAE 100-55 are larger and thus significantly less dusty than comparable 100-55 coating grades – much easier to work with for your operators:
Equivalent drug release
Despite its advantages in handling, Kollicoat® MAE 100-55 provides equivalent drug release as existing comparable coating grades in the market. And this means you can directly introduce it into your commercialized formulations.
Coated Bupropion HCl tablets (150mg);
N = 3; 50 rpm;
Buffer change after 2 h;
880ml HCl + 20 ml Tri-K phosphate
N = 3; 50 rpm;
Buffer change after 2 h;
880ml HCl + 20 ml Tri-K phosphate
Quality and regulatory status
Kollicoat® MAE 100-55 is produced in Germany under GMP conditions. It complies to respective Ph.Eur., USP-NF, and JPE monographs:
| Product Details | |
|---|---|
| Ph.Eur. | Methacrylic Acid – Ethyl Acrylate Copolymer (1:1) Type A |
| USP/NF | Methacrylic Acid and Ethyl Acrylate Copolymer NF (revision Dec 1st, 2015) |
| JPE | Dried Methacrylic Acid Copolymer LD |
Discover more about Kollicoat® MAE 100-55
Enteric Release
Functional solutions for formulations with enteric drug release
-
1
